Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
ADARx Pharmaceuticals, Inc.
Study ID
NCT06990269
Phase
PHASE2
Status
Recruiting

Conditions

  • Geographic Atrophy Secondary to Age-related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
60 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ADX-038 — DRUG
    siRNA duplex oligonucleotide
  • Placebo — DRUG
    Saline

Study Details

Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.

Key Dates

Start date
Nov 10, 2025
Status verified
Apr 2026
Primary completion
Feb 28, 2030
Completion
Aug 30, 2030

Study Design

Enrollment
240 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Active - ADX-038
  • Placebo Comparator: Placebo - Saline

Primary Outcome Measure

Evaluate the effect of ADX-038 on the preservation of the EZ layer [ Time Frame: 12 months ]

Central Contacts

Locations (17)

FacilityCityStateZIPSite coordinators
ADARx Clinical SiteGilbertArizona85297-
ADARx Clinical SitePhoenixArizona85020-
ADARx Clinical SiteBeverly HillsCalifornia90211-
ADARx Clinical SiteHuntington BeachCalifornia93647-
ADARx Clinical SitePowayCalifornia92064-
ADARx Clinical SiteOrlandoFlorida32806-
ADARx Clinical SiteWildwoodFlorida34785-
ADARx Clinical SiteHagerstownMaryland21740-
ADARx Clinical SiteRenoNevada89502-
ADARx Clinical SiteEriePennsylvania16505-
ADARx Clinical SiteAustinTexas78705-
ADARx Clinical SiteDallasTexas75231-
ADARx Clinical SiteMcAllenTexas78503-
ADARx Clinical SiteRound RockTexas78681-
ADARx Clinical SiteSan AntonioTexas78340-
ADARx Clinical SiteThe WoodlandsTexas77384-
ADARx Clinical SiteSt. GeorgeUtah84790-

Find similar trials in Gilbert, AZ

Related Studies